Life Sciences
Our global Life Sciences team comprises a multi-disciplinary group of professionals, acting for businesses across the pharmaceuticals, biotech, veterinary, consumer health, med tech, and diagnostics sub-sectors.
Our experts advise across the entire product cycle - from product development, clinical trials to market entry, advice on reimbursement claims in Germany and pan-European locations, and post-market pharmacovigilance.
The sector team operates on a cross-border basis and covers the full spectrum of legal support. We advise on mergers and acquisitions, IP (both contentious and non-contentious), regulatory, dispute resolution, commercial transactions (including licensing and collaborations) as well as capital markets and finance.
Our international network ensures that we have a ready resource of expertise in a number of jurisdictions, including those in emerging markets, and that we are in the pole position to advise on cross-border work.
News and insights
News: 09 February 2024
Allen & Overy advises Sartorius group on EUR1.4bn equity raising
Frankfurt am Main - Allen & Overy has advised the Sartorius group on equity raisings with a total volume of EUR1.4bn. The transaction comprised the placement of 613,497 preference shares currently…
Publications: 20 December 2023
UPC Insights: Security for legal costs
The UPC decides that the defendant’s financial situation and location matter.
Blog Post: 17 July 2023
When is the composition of a product on the market prior art?
G1/23 – EPO Enlarged Board of Appeals of the EPO “available” (referral from T 0438/19) Under which circumstances can the public prior use of a product constitute prior art for novelty or inventive…
Blog Post: 28 November 2022
Webinar - EU developments in pricing and reimbursement
Keeping up with current developments regarding pricing and reimbursement of pharmaceuticals is crucial for planning efficient and successful market access strategies. The regulatory framework…